Descripción:

S1011 Follow-Up Form (#56311) Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9339E952-BB3F-996A-E040-BB89AD43480C

Link:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9339E952-BB3F-996A-E040-BB89AD43480C
Palabras clave:
Versiones (2)
  1. 26/8/12 26/8/12 -
  2. 9/1/15 9/1/15 - Martin Dugas
Subido en:

9 de enero de 2015

DOI:
Para solicitar uno, por favor iniciar sesión.
Licencia :
Creative Commons BY-NC 3.0 Legacy
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Bladder Cancer NCT01224665 Follow-Up - S1011 Follow-Up Form (#56311) - 3152339v1.0

Inglés
Detalles

Instructions: Please submit at each follow up after completion of treatment until relapse or progression, at time of relapse or progression, and at protocol-specified intervals after relapse or progression. Also submit at time of diagnosis of second primary. All dates are MONTH, DAY, YEAR. Answer all questions and explain any blank fields or blank dates in the Comments section. Place an X in appropriate boxes. Circle AMENDED items in red

1 formularios  
Header
Vital Status
Vital Status
Has the patient had a documented clinical assessment for this cancer (since submission of the previous follow-up form)
Has the patient developed a first relapse or progression that has not been previously reported
Site(s) of Relapse or Progression (select all that apply)
Has a new primary cancer or MDS been diagnosed that has not been previously reported? (myelodysplastic syndrome)
Has the patient received any non-protocol cancer therapy not previously reported (prior to progression/relapse)
Has the patient experienced (prior to treatment for progression or relapse or a second primary, and prior to non-protocol treatment) any severe (grade >=3) long term toxicity that has not been previously reported?
Comments
Volver a la parte superior de la página

Similar models

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial